(19)
(11) EP 1 545 662 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.05.2020 Bulletin 2020/21

(45) Mention of the grant of the patent:
04.03.2020 Bulletin 2020/10

(21) Application number: 03784026.1

(22) Date of filing: 18.07.2003
(51) International Patent Classification (IPC): 
A61M 5/20(2006.01)
 A61M 37/00(2006.01)
(86) International application number:
PCT/EP2003/007859
(87) International publication number:
WO 2004/014468 (19.02.2004 Gazette 2004/08)

(54)

DRUG DELIVERY SYSTEM

VERABREICHUNGSSYSTEM FÜR ARZNEIEN

SYSTEME D'ADMINISTRATION DE MEDICAMENT

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 05.08.2002 GB 0218126

(43) Date of publication of application:
29.06.2005 Bulletin 2005/26

(73) Proprietor: Enesi Pharma Limited
Abingdon, Oxfordshire OX14 4SA (GB)

(72) Inventors:
  • POTTER, Charles David Ogilvy
    Oxon OX8 7SG (GB)
  • POTTER, David Stuart
    Cowes, Isle of Wight (GB)

(74) Representative: Stratagem IPM Limited 
Meridian Court Comberton Road
Toft, Cambridge CB23 2RY
Toft, Cambridge CB23 2RY (GB)


(56) References cited: : 
EP-A- 0 879 609
DE-A- 3 839 287
GB-A- 993 309
US-A- 4 518 387
US-A- 5 542 920
 WO-A1-03/023773
FR-A- 2 749 764
US-A- 2 398 544
US-A- 4 871 094
US-B1- 6 203 521
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).